Ruxolitinib for Treatment of Polycythemia Vera and Myelofibrosis in Patients After Liver Transplantation

Overview

Journal Clin Case Rep

Date 2021 Sep 10

PMID 34504700

Citations 1

Authors

Leona Dold

Philipp Lutz

Annkristin Heine

Tobias J Weismuller

Christian P Strassburg

Ulrich Spengler

Affiliations

Soon will be listed here.

Abstract

Although ruxolitinib contributes to immunomodulation and can lead to severe infections, it seems a feasible treatment strategy for patients with polycythemia vera and myelofibrosis after liver transplantation.

Citing Articles

Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation.

Dold L, Lutz P, Heine A, Weismuller T, Strassburg C, Spengler U Clin Case Rep. 2021; 9(9):e04782.

PMID: 34504700 PMC: 8418679. DOI: 10.1002/ccr3.4782.

References

Escamilla Gomez V, Garcia-Gutierrez V, Lopez Corral L, Garcia Cadenas I, Perez Martinez A, Marquez Malaver F . Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplant. 2019; 55(3):641-648. PMC: 7051903. DOI: 10.1038/s41409-019-0731-x. View

Schonberg K, Rudolph J, Wolf D . NK cell modulation by JAK inhibition. Oncoscience. 2015; 2(8):677-8. PMC: 4580057. DOI: 10.18632/oncoscience.224. View

Verstovsek S, Mesa R, Gotlib J, Gupta V, Dipersio J, Catalano J . Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017; 10(1):55. PMC: 5322633. DOI: 10.1186/s13045-017-0417-z. View

Heine A, Held S, Daecke S, Wallner S, Yajnanarayana S, Kurts C . The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood. 2013; 122(7):1192-202. DOI: 10.1182/blood-2013-03-484642. View

Dold L, Lutz P, Heine A, Weismuller T, Strassburg C, Spengler U . Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation. Clin Case Rep. 2021; 9(9):e04782. PMC: 8418679. DOI: 10.1002/ccr3.4782. View

Melear J, Goldstein R, Levy M, Molmenti E, Cooper B, Netto G . Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation. 2002; 74(8):1090-5. DOI: 10.1097/00007890-200210270-00006. View

Vannucchi A . Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015; 372(17):1670-1. DOI: 10.1056/NEJMc1502524. View

Morton L, Gibson T, Clarke C, Lynch C, Anderson L, Pfeiffer R . Risk of myeloid neoplasms after solid organ transplantation. Leukemia. 2014; 28(12):2317-23. PMC: 4197126. DOI: 10.1038/leu.2014.132. View

Wu B, Ingersoll K, Jug R, Yang L, Luedke C, Lo A . Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 23 Cases. Am J Clin Pathol. 2017; 149(1):55-66. DOI: 10.1093/ajcp/aqx133. View

10.

Heine A, Brossart P, Wolf D . Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?. Blood. 2013; 122(23):3843-4. DOI: 10.1182/blood-2013-10-531103. View

11.

Fung J, Jain A, Kwak E, Kusne S, Dvorchik I, Eghtesad B . De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl. 2001; 7(11 Suppl 1):S109-18. DOI: 10.1053/jlts.2001.28645. View

12.

Quinlan S, Morton L, Pfeiffer R, Anderson L, Landgren O, Warren J . Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients. Cancer Epidemiol Biomarkers Prev. 2010; 19(5):1229-37. PMC: 2866098. DOI: 10.1158/1055-9965.EPI-09-1220. View